Warning: mail() has been disabled for security reasons in /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php on line 110

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-content/plugins/bigcontact/BigContact.php on line 43
All Signals Lead to a Bearish Oil Market But Not for These Penny Stocks | US Market Buzz
Connect with us

Market

All Signals Lead to a Bearish Oil Market But Not for These Penny Stocks

Published

on

Oil increased on Tuesday following one of the largest selloffs this year but looked helpless to additional declines after China’s stock market took another hit and Greece moves closer to exiting the euro zone. U.S crude traded at $53.10 up $0.57 from Monday’s close. Oil has not seen these types of levels since Mid-April. With that being said, penny stocks in the U.S market have not been affected by China or Greece’s economic meltdown. Axxess Pharma Inc. (OTCMKTS:AXXE), FBEC Worldwide Inc. (OTCMKTS:FBEC) and Pervasip Corp. (OTCMKTS:PVSP) have been gaining more attention from investors as of late.

Axxess Pharma Inc, a company that develops a variety of nutritional supplements and specialty pharmaceutical products through its subsidiary company AllStar Health Brands Inc. recently announced the hiring of Michael Gelmon as a their top legal and sales veteran to help in business development and SEC compliance. Prior to coming to Axxes Pharma Mr. Gelmon ran a start-up company that generated more than $300 million in sales. Dr. Bagi, President of Axxess Pharma, quoted: “Mr. Gelmon is an excellent addition to our company. He has strong legal, sales and public company experience. He has also founded and managed a company that went from zero sales to $300 million in sales.” Dr. Bagi continued: “Mr. Gelmon will be working closely with our management in the areas of business development, sales, SEC compliance, accounting and hiring.” In the last week AXXE price per share is up 91.25% from lows in late June of $0.024 to a high of $0.0459 on Tuesday.

FBEC Worldwide, Inc. has been making headway in the explosive cannabis space. The company is set to launch its first H.E.M.P. infused energy shot called, “The WolfShot” in August 2015. The company recently announced it has retained ownership and rights to its hemp-based formulation developed by Dr. Linda Strause of G. Randall & Sons. CEO Robert Sand states, “Working with leading formulation scientists like Dr. Strause is a crucial component needed to carve out a true market niche. We believe hemp-based beverages do just that and we are confident our collaboration with Dr. Strause on our soon-to-launch products with our now 100%-owned hemp-formulation will solidify our place in the market while we work to build a strong following of consumers.” FBEC opened at $0.03 back in early May and saw an impressive run to highs of $0.14 in late June. FBEC is currently seeing trading levels between $0.08-$0.10.

Pervasip Corp. develops and delivers proprietary products and technologies to emerging markets, with a focus on emerging agricultural markets. On July 2nd the company announced it has acquired 100% of Plaid Canary Corporation. Paul Riss, company CEO states, “We are proud and excited to complete this acquisition,” he continued with, “We believe that the opportunities in this market are simply remarkable. We plan to expand Grow Big’s reach and to establish its Denver footprint as a model for long-term growth in other regional markets as conditions warrant.” Over the last month, PVSP has seen a pps spike of 320% from lows of $0.0005 in June to highs of $0.0021 this past Monday.

Biotech

CytoDyn Inc (OTCMKTS:CYDY) Regains Momentum After The Big Announcement

Published

on

By

Now that the market seems to be coming back into his elements, it could be time for investors to start looking into penny stocks more closely. These stocks may often be risky, but if one makes the right choice, then the rewards could be enormous. One penny stock that could be put into the watch list at this point in time is that of CytoDyn Inc (OTCMKTS:CYDY).

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

Continue Reading

Market

These 3 Pot Stocks Are Up Big Since May: What’s the Buzz?

Published

on

By

Over the course of the past year or so, pot stocks had generally struggled, but during the past month, those stocks have recovered nicely. The stock market suffered a historic fall due to the economic turmoil caused by the coronavirus pandemic. It is believed that investors who are looking for value have descended on the beaten-down pot stocks. On the flip side, these stocks could also have been identified as defensive plays in an uncertain market environment.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending